Bevacizumab(Avastin)抑制角膜新生血管的应用新进展
荆国利1,2，高晓唯2，肖云2
作者单位：1(832000)中国新疆维吾尔自治区石河子市，石河子大学医学院研究生院；2（830011）中国新疆维吾尔自治区乌鲁木齐市，解放军474医院 全军眼科中心
作者简介：荆国利，男，石河子大学2006级眼科硕士研究生，研究方向：角膜病与白内障。
通讯作者：荆国利. [email protected]
收稿日期:2008-02-02修回日期:2008-05-12
Advances in application of Bevacizumab(Avastin) inhibiting corneal neovascularization
Guo-Li Jing1,2, Xiao-Wei Gao2,Yun Xiao2
1Postgraduate Research Institute, Medical College of Shihezi University, Shihezi 832000, Xinjiang Uyghur Autonomous Region, China;2Ophthalmic Center, No.474 Hospital of Chinese PLA, Urumqi 830011, Xinjiang Uyghur Autonomous Region China
Correspondence to: Guo-Li Jing. Postgraduate Research Institute, Medical college of Shihezi University, Shihezi 832000, Xinjiang Uyghur Autonomous Region, China. [email protected]
Received:2008-02-02Accepted:2008-05-12
Abstract
The factors triggering corneal neovascularization involve various growth factors. The data supporting a causal role for vascular endothelial growth factor (VEGF) in corneal neovascularization are extensive. One possible strategy for treating corneal neovascularization is to inhibit VEGF activity by competitively binding VEGF with a specific neutralizing anti-VEGF antibody. The vireo-retinal service in recent years enjoyed a high level of success in managing choroid neovascularization using anti-VEGF strategies. Efficacy and tolerability have been demonstrated for drugs targeting VEGF. We herein hypothesized that topical application of new anti-VEGF agents such as pegaptanib, ranibizumab and bevacizumab were potentially useful for inhibiting corneal neovascularization and restoration of corneal clarity.
KEYWORDS: corneal neovascularization；vascular endothelial growth factor；bevacizumab；treatment
Jing GL, Gao XW, Xiao Y. Advances in application of Bevacizumab(Avastin) inhibiting corneal neovascularization. Int J Ophthalmol (Guoji Yanke Zazhi)2008;8(6):1233-1235
摘要
诱发角膜新生血管的因素涉及各种生长因子。研究表明：在角膜新生血管中广泛存在的血管内皮生长因子（vascular endothelial growth factor, VEGF）起着主要作用。一种可行的治疗角膜新生血管策略是：通过特异性的中和抗VEGF抗体竞争性的结合VEGF，从而抑制VEGF活性。近年来，利用抗VEGF治疗策略，抑制脉络膜新生血管获得了很好的效果。靶向VEGF治疗药物的疗效和安全性已经证明。因此我们设想，局部应用新的抗VEGF药物，如贝伐单抗、兰尼单抗等可以有效地抑制角膜新生血管，恢复角膜透明和视力。
关键词：角膜新生血管；血管内皮生长因子；贝伐单抗；治疗
荆国利,高晓唯,肖云. Bevacizumab(Avastin)抑制角膜新生血管的应用新进展.国际眼科杂志 2008;8(6):1233-1235 |
